stonks4u
Sign up free
BCAX logo

BCAX Bicara Therapeutics Inc. Common Stock

NASDAQ Global Market · Biotechnology · Healthcare

$24.28
+0.65 (+2.75%)

Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works…

Market Cap: $1.60Bwww.bicara.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

103
103105108110
Aug 11Aug 12

Quote

Day Range
$23.27 – $24.33
52-Week Range
$10.29 – $30.99
Volume
$473.0K
Market Cap
$1.60B
50-Day Avg
$25.91
200-Day Avg
$20.34
Prev Close
$23.63
Open
$23.69

Valuation & Ratios

P/E Ratio
-6.68
EPS
$-2.52
P/B Ratio
2.29
P/S Ratio
0.00
Debt/Equity
0.00
Current Ratio
14.58
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-34.4%
Return on Assets
-32.0%
FCF Yield
-11.6%
EV/EBITDA
-6.00

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-137.95M$-2.52
2024$0.00$-68.00M$-1.25
2023$0.00$-51.98M$-1.00
2022$0.00$-37.84M$-0.73

Social Signal Score

58
5d
58
4 mentions
—
30d
58
4 mentions
—
60d
58
4 mentions
—
90d
58
4 mentions
—
news: 4

Earnings

Mon, Nov 9(in 3 months)

Consensus estimate $-0.85 per share

2of 7 quarters beat consensus

Typical surprise -21.8% (median, so one quarter with a near-zero estimate can't distort it)

  • Tue, Aug 11$-0.82 vs $-0.82miss
  • Mon, May 11$-0.93 vs $-0.64miss
  • Thu, Mar 26$-0.68 vs $-0.72beat
  • Mon, Nov 10$-0.67 vs $-0.55miss
  • Tue, Aug 12$-0.50 vs $-0.54beat
  • Tue, May 13$-0.68 vs $-0.40miss

Estimates and results for BCAX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

BCAXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (4)

  • Newsseekingalpha.com·3d ago·Positive

    Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds Bicara Therapeutics (BCAX) is upgraded to 'Buy' on favorable early clinical signals for ficerafusp alfa in head and neck cancer. BCAX's phase 1 data show promising median overall survival, but toxicity and small cohort size warrant caution ahead of pivotal phase 3 readout. Strong cash position ($500M liquidity) supports operations into 2029, enabling pursuit of interim phase 3 results and potential commercialization.

    View source ↗
  • Newsbenzinga.com·3d ago·Negative

    Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results Bicara Therapeutics Inc (NASDAQ:BCAX) reported a narrower-than-expected loss for the second quarter on Tuesday.

    View source ↗
  • Newsseekingalpha.com·4d ago·Positive

    Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript

    View source ↗
  • Newsmarketbeat.com·4d ago·Neutral

    Bicara Therapeutics Q2 Earnings Call Highlights Bicara Therapeutics NASDAQ: BCAX used its second-quarter 2026 earnings call to outline leadership changes, progress in its pivotal head and neck cancer program and plans to expand development of ficerafusp alfa, or FICERA, while reaffirming its cash runway into the first half of 2029.

    View source ↗